Table 7 Limitations of treatment success in first-line ER+, HER2- mBC patients - overall by analysis of categories – from physician survey (n = 103)
Not at all substantial | Not at all substantial | Moderately substantial | Substantial | Very substantial | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | n | % | |
Efficacy | 7 | 6.8% | 12 | 11.7% | 25 | 24.3% | 25 | 24.3% | 34 | 33.0% |
Safety/Tolerability | 5 | 4.9% | 22 | 21.4% | 27 | 26.2% | 35 | 34.0% | 14 | 13.6% |
Adherence | 16 | 15.5% | 29 | 28.2% | 22 | 21.4% | 27 | 26.2% | 9 | 8.7% |
Financial cost of treatments | 2 | 1.9% | 27 | 26.2% | 30 | 29.1% | 35 | 34.0% | 9 | 8.7% |